WEGOVY 1.7mg Injection – Semaglutide 1.7mg

$250

15 products sold in last 13 hours

Selling fast! Over 17 people have in their cart

Wegovy 1.7mg Injection contains semaglutide 1.7mg, a GLP-1 receptor agonist used for chronic weight management in eligible patients. It works by helping regulate appetite, increase feelings of fullness, and reduce food intake when used together with a reduced-calorie diet and increased physical activity.

30 people are viewing this right now

Estimated Delivery : Up to 4 business days
Free Shipping & Returns : On all orders over $200

Guaranteed Safe And Secure Checkout

Description
Reviews(0)

Wegovy 1.7mg Injection contains semaglutide, a long-acting GLP-1 receptor agonist administered once weekly by subcutaneous injection. It is used as part of a comprehensive weight-management program that includes a reduced-calorie diet and increased physical activity.

Semaglutide acts on GLP-1 receptors involved in appetite and food-intake regulation. It can reduce hunger, increase satiety, and slow gastric emptying, which may help patients reduce calorie intake and achieve weight loss over time.

The 1.7mg strength is used during the dose-escalation phase or as a maintenance dose for some patients, depending on individual tolerability and the prescribing clinician’s instructions.

Prescription Required.

Product Information


Product Information	Details
Brand Name	Wegovy
Active Ingredient	Semaglutide
Strength	1.7mg
Dosage Form	Injection
Drug Class	GLP-1 Receptor Agonist
Route	Subcutaneous
Frequency	Once weekly
Primary Use	Chronic weight management
Prescription	Required

How It Works

Semaglutide mimics the action of GLP-1, a naturally occurring hormone involved in appetite regulation and glucose metabolism. It acts on GLP-1 receptors to help increase satiety and reduce hunger and food intake.

Administration

Wegovy is administered once weekly by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection can generally be administered at any time of day, with or without food. Injection sites should be rotated.

Dose escalation should be followed exactly as prescribed to reduce the risk of gastrointestinal adverse effects.

Common Side Effects

Important Safety Information

Serious or clinically important risks can include pancreatitis, gallbladder disease, dehydration and kidney problems, hypoglycemia when used with certain diabetes medicines, and serious hypersensitivity reactions.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not combine Wegovy with other semaglutide-containing products or GLP-1 receptor agonists unless specifically directed by a healthcare professional.

Storage

Store according to the manufacturer’s instructions. Keep refrigerated and protect from light. Do not freeze. Follow the product packaging and prescribing information for specific storage requirements.